Naltrexone intranasal - Opiant Pharmaceuticals
Alternative Names: INDV-4002; OPNT 002Latest Information Update: 06 Mar 2023
At a glance
- Originator Opiant Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor antagonists; Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alcoholism
Most Recent Events
- 02 Mar 2023 Opiant Pharmaceuticals has been acquired by Indivior
- 08 Dec 2022 Naltrexone intranasal is still in phase II trials for Alcoholism in United Kingdom and Hungary (Opiant Pharmaceuticals pipeline, December 2022)
- 14 Nov 2022 Opiant Pharmaceuticals completes enrolment in phase II clinical trial in Alcoholism in United Kingdom and Hungary (Intranasal) (EudraCT2019-002859-42)